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Background: Increased levels of the sugar metabolite methylglyoxal (MG) in vivo were shown to participate in the
pathophysiology of vascular complications in diabetes. Alterations of endothelial nitric oxide synthase (eNOS)
activity by hypophosphorylation of the enzyme and enhanced monomerization are found in the diabetic milieu,
and the regulation of this still remains undefined. Using various pharmacological approaches, we elucidate putative
mechanisms by which MG modulates eNOS-associated functions of MG-stimulated superoxide O•−2
 
production,
phosphorylation status and eNOS uncoupling in EA.hy926 human endothelial cells.
Methods: In cultured EA.hy926 endothelial cells, the effects of MG treatment, tetrahydrobiopterin (BH4; 100 μM) and
sepiapterin (20 μM) supplementation, NOS inhibition by NG-nitro-L-arginine methyl ester (L-NAME; 50 μM), and inhibition of
peroxynitrite (ONOO−) formation (300 μM Tempol plus 50 μM L-NAME) on eNOS dimer/monomer ratios, Ser-1177 eNOS
phosphorylation and 3-nitrotyrosine (3NT) abundance were quantified using immunoblotting. O•−2 –dependent fluorescence
was determined using a commercially available kit and tissue biopterin levels were measured by fluorometric HPLC analysis.
Results: In EA.hy926 cells, MG treatment significantly enhanced O•−2 generation and 3NT expression and reduced Ser-1177
eNOS phosphorylation, eNOS dimer/monomer ratio and cellular biopterin levels indicative of eNOS uncoupling. These
effects were significantly mitigated by administration of BH4, sepiapterin and suppression of ONOO− formation. L-NAME
treatment significantly blunted eNOS-derived O•−2 generation but did not modify eNOS phosphorylation or monomerization.
Conclusion: MG triggers eNOS uncoupling and hypophosphorylation in EA.hy926 endothelial cells associated with O•−2
generation and biopterin depletion. The observed effects of the glycolysis metabolite MG presumably account, at least in
part, for endothelial dysfunction in diabetes.
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Chronic hyperglycemia fosters endothelial dysfunction that
accounts for the pathophysiology of microvascular seque-
lae in diabetes [1,2]. The elevated glycolysis metabolite
methylglyoxal (MG) has been implicated in vascular com-
plications such as hypertension [3], impaired microcircula-
tion [4] and thrombosis [5] in diabetes. The increased MG
affects multi-organ homeostasis by modulating immune
cell functions [6], cytokine induction [7], cytosolic Ca2+ [8],
cellular energy and redox balance [9] and adhesion mole-
cules expression [10] and induces both necrotic [11] and
apoptotic cell death [4].* Correspondence: lixin.liu@usask.ca
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reproduction in any medium, provided the orEndothelial nitric oxide synthase (eNOS) is the predom-
inant and constitutively expressed NOS in vascular endo-
thelial cells and catalyzes the reaction for generation of
nitric oxide (NO) from L-arginine in the presence of the co-
factors tetrahydrobiopterin (BH4) and NADPH [12]. Regu-
lation of eNOS activity is coupled to cytosolic Ca2+ [13]
whereas the expression is regulated by a wide range of tran-
scriptional and posttranscriptional mechanisms [14]. Alter-
ations of NO balance contribute to the pathophysiology of
diabetic complications [15]. Deficiency of either L-arginine
or BH4 results in reduced NO but enhanced superoxide
O•−2
 
production, a functional change of eNOS that is de-
fined as eNOS uncoupling [12]. eNOS uncoupling is associ-
ated with increased eNOS monomerization, tyrosine
nitration and formation of dihydrobiopterin (BH2) andThis is an open access article distributed under the terms of the Creative
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cursor of BH4 and serves as a valuable pharmacological
agent for the study of eNOS uncoupling due to its high cell
permeability as compared to BH4 [18,19]. O•−2 avidly reacts
with NO to form peroxynitrite (ONOO−) which triggers
the oxidation of BH4, impairs eNOS activity and induces
eNOS uncoupling [12,16,20].
Uncoupling of eNOS is the underlying mechanism of
endothelial dysfunction associated with cardiovascular
conditions such as hypertension, stroke, and heart failure
[21,22]. Recently, eNOS uncoupling was shown to partici-
pate in endothelial dysfunction in diabetic mice [23] and
to mediate peripheral neuropathy in diabetic rats [24]. In
Zucker diabetic fatty rats, endothelial dysfunction and de-
creased NO availability were attributed to dissociation of
eNOS from HSP90, an effect elicited by increased calpain
activity [25]. As a myriad of molecules are dysregulated in
diabetes, the specific effects of MG on eNOS uncoupling,
however, remain elusive.
Ramifications of elevated MG levels in hyperglycemia
include impaired NO production and redox imbalance
[26]. Various studies promulgate a possible link between
endothelial dysfunction and functional alterations of
eNOS after MG treatment. To date, however, discrepant
data prevail on MG sensitivity of eNOS functions in differ-
ent model systems. On the one hand, MG was shown to
stimulate transcription of eNOS [27]; while on the other,
abundance of eNOS protein was reduced following MG
treatment [28,29]. In contrast, MG was shown to suppress
eNOS phosphorylation on serine-1179 without affecting
eNOS protein expression [30]. Increased MG levels in pre-
eclamptic vasculature were shown to be coupled with en-
hanced arginase, LOX-1 and tyrosine nitration [31]. The
association between MG-triggered eNOS phosphorylation,
eNOS uncoupling, and oxidative stress in vascular endo-
thelial dysfunction, however, remains ill-defined.
The present study explores the mechanisms of MG-
induced endothelial dysfunction by examining putative
eNOS-associated functions. We elucidate the effects of
exogenous BH4 and sepiapterin administration, NOS
inhibition and suppression of peroxynitrite (ONOO−) for-
mation on O•−2 generation, eNOS monomerization, cellular
biopterin levels, tyrosine nitration, and phosphorylation of
eNOS in EA.hy926 endothelial cells in vitro.
Materials and methods
Cell culture and pharmacological treatments
EA.hy926 cells, the hybrid human umbilical vein endo-
thelial cell line cells [32], were obtained from American
Type Culture Collection (Rockville, MD, USA) and cul-
tured in Dulbecco’s modified Eagle’s medium (Cellgro,
VA, USA) with 10% fetal bovine serum (Hyclone, UT,
USA), 100 U/mL penicillin and 100 μg/mL streptomycin
(Amresco, OH, USA) with 5% CO2 and maximalhumidity at 37°C. Cells between passage 3 and 6 were
used for the experiments. As indicated in the figure
legends, various pharmacological approaches were
used to elucidate eNOS-associated functions. To main-
tain eNOS dimerization, the NOS cofactor 5,6,7,
8-tetrahydrobiopterin (BH4, 100 μM; Sigma-Aldrich,
Oakville, ON, Canada) or the negative control, a pteridine
analogue, 5,6,7,8-tetrahydroneopterin (NH4, 100 μM;
Schircks Laboratories, Jona, Switzerland) were freshly-
prepared and administered. NH4 has similar antioxidant
effects as BH4 but, unlike BH4, is ineffective in restoring
uncoupled eNOS [33]. Sepiapterin (20 μM; Cayman, Ann
Arbor, MI, USA), a substrate for BH4 synthesis via the
pterin salvage pathway, was used to increase cellular BH4
levels [34]. The NOS inhibitor NG-nitro-L-arginine methyl
ester (L-NAME, 50 μM; Sigma-Aldrich), was administered
to inhibit uncoupled eNOS-derived O•−2 [35]. For suppres-
sion of ONOO− generation, EA.hy926 cells were treated
with a combination of the ROS scavenger 1-oxyl-2,2,6,
6-tetramethyl-4-hydroxypiperidine (Tempol, 300 μM; Santa
Cruz, Dallas, TX, USA) and NOS inhibitor L-NAME
(50 μM) for 24 h prior to the addition of MG [36,37].
O•−2 reacts with NO at equimolar ratio to generate
ONOO− [36], and from our unpublished observations,
pretreatment with a combination of L-NAME and Tempol
more potently inhibits ONOO− formation than pretreat-
ment with either pharmacological agent alone.
Determination of O•−2 production
O•−2 levels were determined using a commercial super-
oxide detection kit (Enzo, Brockville, ON, Canada)
according to the manufacturer’s instructions as de-
scribed previously [38,39]. The superoxide detection re-
agent when oxidized produces an orange fluorescent
compound which is retained in the cell. Cells were seeded
in a 96-well plate and stained with the membrane-
permeable and nonfluorescent O•−2 detection probe (5 μM,
30 min, 37°C in the dark). Excessive probe was removed
by washing with PBS. The fluorescence in cells was
detected using excitation and emission wavelengths of 544
nm and 590 nm respectively. The data are expressed as ar-
bitrary units.
Analysis of biopterin levels by HPLC
Measurement of BH4 and total biopterins was per-
formed by fluorometric HPLC analysis as described pre-
viously with slight modifications [35]. After indicated
treatments, EA.hy926 cells were lysed in a lysis buffer
(pH 7.4; containing 50 mM Tris–HCl, 1 mM DTT and 1
mM EDTA) with 0.1 μM neopterin (Sigma-Aldrich)
as an internal recovery standard. The samples were
deproteinated with 10% 1:1 mixture of 1.5 M HClO4 and
2 M H3PO4 and centrifuged (12,000 × g for 10 min).
The supernatant was split into portions and subjected to
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ation of total biopterins (BH4, BH2 and non-reduced
biopterins) by acid-oxidation, 10 μl iodine solution (1%
iodine in 2% KI solution) was added into each 90 μl
supernatant and for quantification of BH2 and non-
reduced biopterins by alkali-oxidation, 10 μl of 1 M
NaOH and 10 μl of iodine solution were added to 80 μl
supernatant. Following incubation (1 h, room tempera-
ture in the dark), the alkali-oxidation samples were acid-
ified with 1 M H3PO4, the iodine in both acid- and
alkali-oxidation samples was reduced using 5% ascorbic
acid (Sigma) and the samples were centrifuged (12,000 ×
g for 10 min). The supernatant was collected for HPLC
analysis using a Hitachi D-7000 HPLC system (Hitachi,
Mississauga, ON, Canada) via Symmetry C18 reverse-
phase column with a methanol–water (1.5:98.5, v/v) mo-
bile phase running at 0.5 mL/min. Fluorescence was
detected at excitation and emission wavelengths of 348
nm and 444 nm respectively. The level of BH4 was cal-
culated by subtracting BH2 and non-reduced biopterins
from total biopterins and expressed as pmol per mg pro-
tein. The biopterin levels in NH4-treated cells were cal-
culated without adding 0.1 μM neopterin.
Western blotting
Non-reducing SDS-PAGE was performed to detect
eNOS dimers and monomers [35]. Briefly, cultured EA.
hy926 cells were harvested and lysed on ice for 30 min
by using RIPA buffer (50 mM Tris–HCl, 150 mM NaCl,
1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and
protease inhibitors cocktail, pH 8.0). The lysate was
centrifuged at 10,000 × g for 10 min, and the super-
natant was collected, incubated with 4 × Laemmli buffer
without β-mercaptoethanol (200 mM Tris–HCl, 50%
glycerol, 2% SDS, 0.04% bromophenol blue, pH 6.8) at
37°C for 5 min. Aliquots of cell lysates (50 μg of protein
each) were separated on 7% SDS-PAGE. Gels and buffers
were equilibrated at 4°C before electrophoresis, and the
buffer tank was placed in an ice bath during electrophor-
esis to maintain the low temperature. Subsequent to
non-reducing SDS-PAGE, the gels were electrotrans-
ferred to a nitrocellulose membrane (Bio-Rad, CA,
USA), and the blots were probed by primary antibody
against eNOS (1:1000; BD Pharmingen, USA) and horse-
radish peroxidase-conjugated secondary antibody (Santa
Cruz) as routine Western blot. In separate gels, total
eNOS (1:1000), β-actin (1:1000; Santa Cruz, CA, USA),
phospho-eNOS (Ser-1177, 1:1000; BD Pharmingen, CA,
USA) and 3-nitrotyrosine (3NT, 1:1000; Enzo) from cell
lysates of the same experiments were detected by rou-
tine Western blot under reduced condition. The bands
were visualized with enhanced chemiluminescence re-
agents (GE Healthcare Life Sciences, NJ, USA) and ex-
posed to X-ray film (Kodak scientific imaging film, ON,Canada). Densitometric quantification of the detected
bands was performed using Quantity One® Software
(Bio-rad). The ratio of eNOS dimer to monomer was
normalized to one in the absence of MG.
Statistical analysis
Data are expressed as arithmetic means ± SEM from at
least three independent experiments. Statistical analysis was
made using one way analysis of variance (ANOVA) with
Tukey’s post-hoc comparison test. n denotes the number of
different batches of cells tested in each treatment group.
Values of p < 0.05 were considered statistically significant.
Results
To elucidate the redox imbalance triggered by MG treat-
ment on vascular endothelial cells in vitro, we analyzed
MG-triggered O•−2 generation using a fluorescence-based
assay. Treatment of EA.hy926 endothelial cells with MG
(50 – 200 μM) for 2, 4, 6 and 8 h respectively, significantly
increased O•−2 production in a concentration- and time-
dependent manner (Figure 1A). In another series of experi-
ments, we analyzed the effect of biopterin supplementation
(BH4, 100 μM; sepiapterin, 20 μM), pharmacological inhib-
ition of NOS using L-NAME (50 μM) or suppression of
ONOO− formation using combined 24-h pretreatment
with Tempol (300 μM) and L-NAME (50 μM) on MG-
induced O•−2 production. As shown in Figure 1B, inhibition
of NOS, suppression of ONOO− formation, or supplemen-
tation of either BH4 or sepiapterin significantly attenuated
MG-induced O•−2 production. Treatment of EA.hy926 cells
with the BH4 control NH4 (100 μM), however, did not sig-
nificantly alter MG-induced O•−2 production (Figure 1B).
These results suggest eNOS-derived O•−2 production in
MG-treated EA.hy296 endothelial cells.
Next, we explored the effect of MG on eNOS monome-
rization in EA.hy926 endothelial cells. Treatment of EA.
hy926 cells with MG (50 – 200 μM) for 0.5, 2, 4, and 8 h
respectively, significantly decreased eNOS dimer/mono-
mer ratio in a concentration- and time-dependent manner
(Figure 2A and 2B). These results, together with the effect
of L-NAME inhibition on MG-induced O•−2 production
(Figure 1B), suggest that MG treatment induces eNOS un-
coupling in EA.hy926 cells. We further tested the effect of
biopterin supplementation, L-NAME addition and sup-
pression of ONOO− formation on MG-elicited eNOS
monomerization. As shown in Figure 2C and 2D, treat-
ment of EA.hy926 cells with MG (100 μM) for 8 h signifi-
cantly reduced eNOS dimer/monomer ratio, an effect that
was significantly blunted by the administration of BH4
(100 μM, 4 h), sepiapterin (20 μM, 4 h) or by ONOO−
suppression (300 μM Tempol and 50 μM L-NAME, 24 h).
Treatment with L-NAME (50 μM, 4 h) alone or the BH4
control NH4 (100 μM, 4 h) did not modify eNOS dimer/
monomer ratio (Figure 2C and 2D).
Figure 1 Methylglyoxal-stimulated O2
•− production in EA.hy926
endothelial cells. A. O•−2 generation determined in EA.hy296
endothelial cells treated with different concentrations of MG (0, 50,
100 and 200 μM) for 0, 2, 4, 6 and 8 h respectively. Data are
arithmetic means ± SEM (n = 6). * indicates significant difference (p
< 0.05) from the absence of MG (ANOVA). B. O•−2 generation
determined in EA.hy296 endothelial cells treated with MG (100 μM)
for 8 h in the absence (Control) or in the presence of L-NAME (50
μM), BH4 (100 μM), NH4 (100 μM) or sepiapterin (20 μM) in the last
4 h of MG treatment or 24-h pre-treatment with 300 μM Tempol
and 50 μM L-NAME (ONOO− suppression) prior to the addition of
MG. Data are arithmetic means ± SEM (n = 6). * indicates significant
difference (p < 0.05) from Control (ANOVA).
Figure 2 Methylglyoxal-induced eNOS monomerization in EA.
hy926 endothelial cells. A and B. Original Western blots (A) and the
respective densitometric analysis (B) of the relative abundance of
eNOS dimers over eNOS monomers (relative to β-actin) in EA.hy296
endothelial cells treated with different concentrations of MG (0 μM,
circles; 50 μM, triangles; 100 μM, squares; and 200 μM, diamonds) for
0.5, 2, 4, and 8 h respectively. Data are arithmetic means ± SEM (A,
representative of five experiments; B, n = 5). * indicates significant
difference (p < 0.05) from the absence of MG (ANOVA). # indicates
significant difference (p < 0.05) from time 0.5 h (ANOVA). C and D.
Original Western blots (C) and the respective densitometric analysis (D)
of the relative abundance of eNOS dimers over eNOS monomers
(relative to β-actin) in EA.hy296 endothelial cells incubated in the
absence (−) or in the presence of MG (100 μM) for 8 h alone (+) or
with 100 μM BH4, 100 μM NH4, 20 μM sepiapterin or 50 μM L-NAME in
the last 4 h of MG treatment or with 24-h pre-treatment with 300 μM
Tempol and 50 μM L-NAME (ONOO− suppression). Data are arithmetic
means ± SEM (C, representative of four experiments; D, n = 4). *
indicates significant difference (p < 0.05) from the absence of MG
(ANOVA). # indicates significant difference (p < 0.05) from MG
treatment alone (ANOVA).
Su et al. Cardiovascular Diabetology 2013, 12:134 Page 4 of 9
http://www.cardiab.com/content/12/1/134To further elucidate MG-induced eNOS uncoupling,
we determined the cellular BH4 levels in EA.hy926 cells
following MG treatment. As depicted in Figure 3A,
treatment of EA.hy926 cells with MG (50 – 200 μM) for
8 h significantly decreased total cellular biopterin and
BH4 levels in a concentration-dependent manner. More
importantly, treatment of EA.hy926 cells resulted in a
reduction of BH4/total biopterin ratio, an effect reaching
statistical significance at 100 μM MG concentration
Figure 3 Effect of methylglyoxal on cellular biopterin levels in EA.hy926 endothelial cells. A and B. Total cellular biopterin (pmol/mg
protein; black bars; A) and BH4 (pmol/mg protein; white bars; A) and the respective BH4/total biopterin ratio (B) determined in EA.hy296 endothelial
cells treated with different concentrations of MG (0, 50, 100 and 200 μM) for 8 h. Data are arithmetic means ± SEM (n = 5). * indicates significant
difference (p < 0.05) from the absence of MG (ANOVA). C and D. Total cellular biopterin (pmol/mg protein; black bars; C) and BH4 (pmol/mg protein;
white bars; C) and the respective BH4/total biopterin ratio (D) determined in EA.hy296 endothelial cells treated with MG (100 μM) for 8 h in the
absence (Control) or in the presence of L-NAME (50 μM), BH4 (100 μM), NH4 (100 μM) or sepiapterin (20 μM) in the last 4 h of MG treatment or with
24-h pre-treatment with 300 μM Tempol and 50 μM L-NAME (ONOO− suppression). Data are arithmetic means ± SEM (n = 5). * indicates significant
difference (p < 0.05) from Control (ANOVA).
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plementation, L-NAME addition and suppression of
ONOO− formation on MG-induced reduction in cellular
BH4 levels. As illustrated in Figure 3C, 4-h supplementa-
tion of BH4 (100 μM) or sepiapterin (20 μM) in MG-
treated EA.hy926 cells significantly increased total cellular
biopterin and BH4 levels suggesting that exogenous
biopterin repletion dissipated MG-induced reduction in
cellular BH4 contents associated with eNOS uncoupling.
Suppression of ONOO−, however, did not significantly
modify total cellular biopterin levels but significantly in-
creased cellular BH4 levels in MG-treated cells (Figure 3C).
Neither the BH4 control NH4 (100 μM) nor L-NAME (50
μM) alone significantly altered cellular BH4 and total
biopterin levels (Figure 3C). Similarly, MG-induced reduc-
tion of cellular BH4/total biopterin ratio was significantly
attenuated by supplementation with BH4 or sepiapterin or
by ONOO− suppression but not by the BH4 control NH4
or by L-NAME alone (Figure 3D).
Uncoupling of eNOS is associated with enhanced cel-
lular nitration of tyrosine [17]. In a further series of ex-
periments we examined the abundance of 3NT in EA.hy926 cells treated with MG and the effect of biopterins, L-
NAME or ONOO− suppression after MG. As shown in
Figure 4, treatment of EA.hy926 cells with 100 μM of MG
for 8 h significantly increased the expression of 3NT, an ef-
fect that was significantly blunted by BH4 (100 μM, 4 h),
sepiapterin (20 μM, 4 h) or ONOO− suppression (300 μM
Tempol and 50 μM L-NAME, 24 h) but not by the BH4
control NH4 (100 μM, 4 h) or L-NAME (50 μM, 4 h)
suggesting that biopterin-sensitive eNOS uncoupling was
triggered by MG (Figure 4A and 4B). The effect of ONOO−
suppression on the reduction of 3NT expression by the
combination of Tempol (300 μM) and L-NAME (50 μM)
was higher than the administration of Tempol (300 μM)
alone (data not shown).
To further unravel the modulation of eNOS functions
by MG, we investigated the effect of biopterin supple-
mentation, ONOO− suppression and NOS inhibition on
eNOS phosphorylation (Ser-1177) associated with eNOS
uncoupling. To this end, treatment of EA.hy926 cells
with 100 μM of MG for 8 h did not modify total eNOS
but significantly decreased phosphorylation of eNOS
(Ser-1177), an effect that was significantly blunted by
Figure 4 Effect of methylglyoxal on tyrosine nitration in EA.
hy926 endothelial cells. A and B. Original Western blots (A) and
the respective densitometric analysis (B) of the relative abundance of
3-nitrotyrosine (relative to β-actin) in EA.hy296 endothelial cells
incubated in the absence (−) or in the presence of MG (100 μM) for 8
h alone (+) or with 100 μM BH4, 100 μM NH4, 20 μM sepiapterin, or 50
μM L-NAME in the last 4 h of MG treatment or with 24-h pre-treatment
with 300 μM Tempol and 50 μM L-NAME (ONOO− suppression). Data
are arithmetic means ± SEM (A, representative of three experiments; B,
n = 3). * indicates significant difference (p < 0.05) from the absence of
MG (ANOVA). # indicates significant difference (p < 0.05) from MG
treatment alone (ANOVA).
Figure 5 Effect of methylglyoxal on eNOS phosphorylation in
EA.hy926 endothelial cells. A and B. Original Western blots (A)
and the respective densitometric analysis (B) of the relative
abundance of total eNOS protein (white bars; relative to β-actin) and
Ser-1177 phospho-eNOS (black bars; relative to β-actin) in EA.hy296
endothelial cells incubated in the absence (−) or in the presence of
MG (100 μM) for 8 h alone (+) or with 100 μM BH4, 100 μM NH4, 20
μM sepiapterin or 50 μM L-NAME in the last 4 h of MG treatment or
with 24 h pre-treatment with 300 μM Tempol and 50 μM L-NAME
(ONOO− suppression). Data are arithmetic means ± SEM (A,
representative of three experiments; B, n = 3). * indicates significant
difference (p < 0.05) from the absence of MG (ANOVA). # indicates
significant difference (p < 0.05) from MG treatment alone (ANOVA).
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sion but not by the BH4 control NH4 (100 μM) or L-
NAME (50 μM) suggesting that both eNOS phosphoryl-
ation (Ser-1177) and eNOS uncoupling are closely linked to
MG-triggered endothelial dysfunction (Figure 5A and 5B).
Discussion
In this study we provide conclusive biological evidence
that treatment of EA.hy926 endothelial cells with MG
triggers eNOS hypophosphorylation and eNOS uncoup-
ling in vitro. We show that MG treatment enhances O•−2
generation and 3NT expression and decreases Ser-1177
phosphorylated eNOS, eNOS dimer/monomer ratio
and cellular levels of BH4 and BH4/total biopterin
ratio in endothelial cells. Moreover, we demonstrate
that pharmacological suppression of eNOS uncoupl-
ing by L-NAME, exogenous BH4 or sepiapterin ad-
ministration, and ONOO− suppression counteracted
MG-induced eNOS uncoupling, 3NT upregulation and
eNOS hypophosphorylation.Oxidative stress is a salient feature of the pathophysi-
ology of diabetes. The glycolysis metabolite MG was pre-
viously shown to affect redox balance by stimulating
ROS production and modulating the expression and
functions of cytoprotective molecules such as glutathi-
one [40], superoxide dismutase [41], glyoxalase [42] and
H2S [43]. Increased NADPH oxidase-derived O
•−
2 reacts
with eNOS-derived NO to generate ONOO− which oxi-
dizes BH4 to BH2. BH4 reduction has been implicated
in the pathogenesis of a variety of conditions such as
hyperphenylalaninemia [44], diabetes [45], ischemia-
reperfusion injury [46], hypertension [47], Alzheimer
disease and Parkinson’s disease [48], and many of these
pathological conditions were shown to be ameliorated
by exogenous BH4 [44-47] or sepiapterin [49-51]
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nance of eNOS dimers and is functionally related to
S-glutathionylation, a powerful regulator of eNOS un-
coupling [52]. Our data that MG-triggered O•−2 gener-
ation was inhibitable by L-NAME addition, BH4 or
sepiapterin supplementation and ONOO− suppression
clearly suggest the presence and contribution of un-
coupled eNOS to O•−2 generation in endothelial cell
functions triggered by MG.
Mounting evidence suggests that phosphorylation of
the residue Ser-1177 of eNOS via AKT stimulates NO
production [53]. The effects of eNOS phosphorylation
on eNOS uncoupling and O•−2 production are not com-
pletely understood. Ser-1177 phosphorylation was shown
to inhibit the Ca2+ sensitivity of eNOS and thus fosters
Ca2+-independent O•−2 generation [54]. In this study we
tested the effect of BH4 supplementation on the hitherto
known reduction of eNOS phosphorylation triggered by
MG [30]. Our data show that supplementation of either
BH4 or sepiapterin reversed MG-triggered reduction in
Ser-1177 eNOS phosphorylation and enhanced eNOS un-
coupling. Similar to BH4, other pharmacological agents
such as nifedipine [55], nicorandil [56], and telmisartan
[57] were shown to inhibit eNOS uncoupling and enhance
eNOS phosphorylation and may, therefore, be beneficial in
diabetic endothelial dysfunction. Furthermore, endogenous
mediators such as C-reactive protein [58], IGF-1 [59],
calcitriol [60], and 20-hydroxyeicosatetraenoic acid [61]
were reported to modulate eNOS-associated functions. In
this study we demonstrate for the first time the eNOS
monomerization induced by the glycolysis metabolite MG
and the effects of BH4 and sepiapterin supplementation on
MG-modulated eNOS-associated functions in endothelial
cells.
Uncoupling of eNOS is characterized by augmented
tyrosine nitration which strongly indicates ONOO−-tri-
ggered cellular injury in diabetic hyperglycemia
[62]. Increased placental protein tyrosine nitration was
documented in diabetic patients [63] and, in animal
models of diabetes, 3NT was shown to be enhanced in
the kidney [64] and in the ventricle and lens [65]. Simi-
larly, 3NT is upregulated in diabetic cardiomyopathy
[66]. Our finding that BH4 but not NH4 supplementa-
tion abrogated enhanced 3NT expression in MG-treated
endothelial cells supports the view that MG-induced de-
pletion of eNOS factor BH4 is critical for MG-triggered
eNOS uncoupling and endothelial dysfunction. Similar
observations were also made in the diabetic heart sub-
jected to ischemia-reperfusion injury [46], clearly indicat-
ing that exogenous BH4 supplementation may ameliorate
diabetes-associated multi-organ pathologies.
Conflicting reports on eNOS expression in diabetic
endothelial dysfunction suggest the complexity of the
signalling mechanisms associated with eNOS duringhyperglycemia. Treatment of endothelial cells with high
concentrations of glucose was reported to have de-
creased eNOS protein expression in vitro [67]. It was
also reported that the abundance of total and phosphor-
ylated eNOS was reduced in internal mammary arteries
of diabetic patients [68]. In old Zucker diabetic fatty rats,
eNOS protein expression was demonstrated to be de-
creased [69]. On the contrary, in diabetic and apolipo-
protein E-deficient mice, eNOS mRNA levels were
augmented [70]. In a contrasting report, however, eNOS
expression was shown to be unaltered in type 2 diabetic
db/db mice [71]. Along those lines, the discordant effects
of MG treatment on eNOS functions reported previously
may, thus, not be unexpected [27-30]. It is, however, intri-
guing to speculate that MG may be one of the essential
metabolites that triggers eNOS hypophosphorylation and
uncoupling encountered in diabetes.
Conclusions
We conclude that the intermediate glycolysis metabolite
MG is a powerful modulator of eNOS functions in vas-
cular endothelial cells in vitro. Administration of BH4
or its precursor sepiapterin or suppression of ONOO−
formation replenishes cellular BH4 levels, reverses
hypophosphorylation of eNOS and ameliorates O•−2 gen-
eration, 3NT upregulation and eNOS monomerization
that are associated with MG-triggered eNOS uncoupling
in endothelial cells. These pharmacological measures
may indicate promising therapeutic benefits in MG-
sensitive endothelial dysfunction in diabetes.
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